Indication

Non-small cell lung cancer with EGFR exon 20 insertion mutation

Non-small cell lung cancer with EGFR exon 20 insertion mutation represents a distinct molecular subset of non-small cell lung cancer characterized by in-frame duplications or insertions within exon 20 of the epidermal growth factor receptor gene. Read more about Non-small cell lung cancer with EGFR exon 20 insertion mutation

4 drugs 3 manufacturers

Advertisement

Drugs that treat it

Common Non-small cell lung cancer with EGFR exon 20 insertion mutation therapies.

Showing 1–4 of 4 drugs

RYBREVANT (amivantamab-vmjw)

ANTINEOPLASTIC - BISPECIFIC EGFR AND MET REC INHIBITOR MC AB·NON-SMALL CELL LUNG CANCER WITH EGFR EXON 19 DELETION·+2
JANSSEN BIOTECH, Inc.

ZEGFROVY (sunvozertinib)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATION
DIZAL/ASTRAZENE
Filter & compare in the drug finder →Opens the drug finder with Non-small cell lung cancer with EGFR exon 20 insertion mutation preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Non-small cell lung cancer with EGFR exon 20 insertion mutation.

Non-small cell lung cancer with EGFR exon 20 insertion mutation represents a distinct molecular subset of non-small cell lung cancer characterized by in-frame duplications or insertions within exon 20 of the epidermal growth factor receptor gene.

Primarily affecting the pulmonary epithelial tissue, these alterations typically occur in adenocarcinomas and are enriched among non-smokers and female patients.

Pathophysiologically, the insertion alters the conformation of the kinase domain's alpha-C-helix and phosphate-binding loop, locking the receptor into a constitutively active state that drives malignant cell proliferation and survival.

Unlike classic sensitizing EGFR alterations, these structural changes sterically restrict the drug-binding pocket, conferring intrinsic de novo resistance to first-, second-, and third-generation tyrosine kinase inhibitors.

Personalize your experience

Follow Non-small cell lung cancer with EGFR exon 20 insertion mutation and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it